liver transplantation |
71 |
hepatocellular carcinoma |
57 |
adult |
51 |
humans |
47 |
female |
38 |
male |
37 |
medical sciences |
37 |
middle aged |
37 |
hepatectomy |
33 |
aged |
28 |
recurrence |
28 |
surgery |
27 |
gastroenterology medical sciences |
26 |
hcc |
25 |
prognosis |
25 |
retrospective studies |
25 |
treatment outcome |
25 |
survival analysis |
24 |
liver cancer |
23 |
living donors |
23 |
survival |
23 |
graft survival |
21 |
hong kong - epidemiology |
21 |
follow-up studies |
20 |
adolescent |
19 |
cirrhosis |
19 |
time factors |
19 |
immunosuppressive agents - therapeutic use |
18 |
liver transplantation - methods |
18 |
antiviral agents - therapeutic use |
17 |
liver resection |
17 |
survival rate |
17 |
aged, 80 and over |
16 |
cadaver |
16 |
disease-free survival |
16 |
gastroenterology |
16 |
hepatectomy - methods |
16 |
hepatocellular carcinoma (hcc) |
16 |
immunohistochemistry |
16 |
liver cirrhosis |
16 |
liver transplant |
16 |
liver transplantation - adverse effects |
16 |
transarterial chemoembolization |
16 |
age factors |
15 |
blood transfusion |
15 |
cell proliferation |
15 |
disease progression |
15 |
reverse transcriptase polymerase chain reaction |
15 |
laparoscopic liver resection |
14 |
outcomes |
14 |
case report |
13 |
cohort studies |
13 |
enzyme-linked immunosorbent assay |
13 |
hepatitis b |
13 |
incidence |
13 |
infant |
13 |
inflammation |
13 |
liver function tests |
13 |
liver transplantation - immunology |
13 |
living donor liver transplant |
13 |
portal vein |
13 |
postoperative complications |
13 |
reoperation |
13 |
ablation |
12 |
acute hepatitis |
12 |
arginine methylation |
12 |
bronchiectasis |
12 |
cancer stemness |
12 |
carcinoma, hepatocellular - mortality - surgery |
12 |
chemicals and cas registry numbers |
12 |
child |
12 |
child, preschool |
12 |
chronic obstructive lung disease |
12 |
drug therapy, combination |
12 |
liver diseases - surgery |
12 |
liver neoplasms - mortality - surgery |
12 |
liver neoplasms - pathology - surgery |
12 |
living donor |
12 |
meld |
12 |
organ size |
12 |
pediatric liver transplantation |
12 |
tissue donors |
12 |
acute disease |
11 |
acute flare |
11 |
apoptosis |
11 |
body mass index |
11 |
cancer staging |
11 |
cancer survival |
11 |
carcinoma, hepatocellular - surgery |
11 |
carrier state |
11 |
decompensation |
11 |
emergencies |
11 |
hepatitis b infection |
11 |
high-intensity focused ultrasound |
11 |
intraoperative complications - epidemiology |
11 |
laparoscopy |
11 |
liver failure |
11 |
liver neoplasms - surgery |
11 |
liver transplantation - statistics & numerical data |
11 |
long-term outcome |
11 |
metastasis |
11 |
outcome |
11 |
prospective studies |
11 |
tumor recurrence |
11 |
allergology and immunology |
10 |
alpps |
10 |
antigens, cd - genetics - metabolism |
10 |
biliary anastomotic stricture |
10 |
bridging therapy |
10 |
carcinoma, hepatocellular - mortality - pathology - surgery |
10 |
cyclosporine - therapeutic use |
10 |
dna primers |
10 |
hepatitis b, chronic - complications |
10 |
hong kong |
10 |
hospital mortality |
10 |
immunosuppression |
10 |
lamivudine |
10 |
length of stay |
10 |
liver neoplasms - mortality - pathology - surgery |
10 |
liver transplantation - methods - statistics and numerical data |
10 |
living donors - supply and distribution |
10 |
morbidity |
10 |
new technology |
10 |
postoperative complications - epidemiology |
10 |
resection |
10 |
scarce deceased donors |
10 |
surgery medical sciences |
10 |
tissue donors - supply and distribution |
10 |
vascular surgical procedures - methods |
10 |
11c-acetate |
9 |
animals |
9 |
bile ducts - surgery |
9 |
blood loss, surgical |
9 |
body weight |
9 |
cancer invasion |
9 |
carcinoma |
9 |
carcinoma, hepatocellular - pathology - surgery |
9 |
chronic disease |
9 |
contrast ct |
9 |
endocrinology |
9 |
epigenetics |
9 |
gpx3 |
9 |
hifu |
9 |
hipsc-mscs |
9 |
hospitals, university |
9 |
invasion |
9 |
invasiveness |
9 |
lamivudine - therapeutic use |
9 |
liver circulation - physiology |
9 |
liver diseases - epidemiology |
9 |
liver failure - surgery |
9 |
liver transplantation - mortality |
9 |
living donor liver transplantation |
9 |
milan criteria |
9 |
mortality |
9 |
neoplasm staging |
9 |
non-invasive treatment |
9 |
palliative care |
9 |
pet/ct |
9 |
postoperative complications - classification - epidemiology |
9 |
rats |
9 |
rats, sprague-dawley |
9 |
reverse transcriptase inhibitors - therapeutic use |
9 |
right liver graft |
9 |
severity of illness index |
9 |
tumor-initiating cells |
9 |
acetic acid c 11 |
8 |
advanced cancer |
8 |
antiviral agents - adverse effects - therapeutic use |
8 |
antiviral therapy |
8 |
base sequence |
8 |
bile leak |
8 |
biliary atresia |
8 |
biliary atresia - complications - surgery |
8 |
biliary complications |
8 |
bilirubin - blood |
8 |
cadaver donor |
8 |
cancer recurrence |
8 |
carcinoma, hepatocellular - complications/diagnosis - surgery |
8 |
carcinoma, hepatocellular - genetics - metabolism |
8 |
carcinoma, hepatocellular - metabolism - pathology |
8 |
carcinoma, hepatocellular - surgery - virology |
8 |
cardiac function |
8 |
carrier proteins - metabolism |
8 |
cell division - physiology |
8 |
cell line, tumor |
8 |
chemokine cxcl1 - physiology |
8 |
cholangiocarcinoma |
8 |
colorectal cancer |
8 |
combined modality therapy |
8 |
complications of liver transplantation |
8 |
cyclin-dependent kinase inhibitor p16 - genetics - metabolism |
8 |
deceased donor liver transplantation |
8 |
disease severity |
8 |
dose-response relationship, drug |
8 |
elasticity imaging techniques - methods |
8 |
fluorodeoxyglucose f 18 |
8 |
focal adhesion kinase 2 - metabolism |
8 |
general surgery |
8 |
gist |
8 |
glycoproteins - deficiency - genetics - metabolism |
8 |
glycoproteins - genetics - metabolism |
8 |
guanine - adverse effects - analogs and derivatives - therapeutic use |
8 |
heme oxygenase-1 |
8 |
hepatectomy - adverse effects |
8 |
hepatectomy - methods - mortality |
8 |
hepatic encephalopathy - surgery |
8 |
hepatitis b antibodies |
8 |
hepatitis b, chronic - complications - diagnosis - drug therapy - surgery |
8 |
hepatitis b, chronic - pathology |
8 |
inhibitor of differentiation protein 1 |
8 |
interleukin-8 - deficiency - genetics - physiology |
8 |
ischemia-reperfusion injury |
8 |
laparoscopic resection |
8 |
liver |
8 |
liver cirrhosis - pathology - virology |
8 |
liver cirrhosis - surgery - virology |
8 |
liver disease |
8 |
liver diseases - etiology - surgery |
8 |
liver failure - etiology - surgery |
8 |
liver failure - pathology - virology |
8 |
liver graft injury |
8 |
liver metastasis |
8 |
liver neoplasms - complications/diagnosis - surgery |
8 |
liver neoplasms - genetics - metabolism |
8 |
liver neoplasms - metabolism - pathology |
8 |
liver transplantation - adverse effects - statistics & numerical data |
8 |
liver transplantation - contraindications - methods - mortality - statistics & numerical data |
8 |
living-donor liver transplantation |
8 |
living-related liver transplantation |
8 |
marginal graft |
8 |
medicine & public health |
8 |
microscopy, electron |
8 |
mitochondrion |
8 |
multivariate analysis |
8 |
neoplasm recurrence, local - surgery |
8 |
neoplastic cells, circulating - pathology |
8 |
nitric oxide synthase type ii |
8 |
organ size - physiology |
8 |
orthotopic liver transplantation |
8 |
patient selection |
8 |
pediatric liver transplant |
8 |
portoenterostomy, hepatic |
8 |
postoperative care |
8 |
postoperative complications - prevention & control |
8 |
preoperative care |
8 |
prevention |
8 |
proportional hazards models |
8 |
radiofrequency ablation |
8 |
reduced-size liver transplant |
8 |
reduced-size liver transplantation |
8 |
renal transplantation |
8 |
repressor proteins |
8 |
retinoblastoma protein - genetics - metabolism |
8 |
rna, messenger - genetics - metabolism |
8 |
salvage transplantation |
8 |
sensitivity and specificity |
8 |
seroconversion (sc) |
8 |
steatosis |
8 |
stereotactic body radiation therapy |
8 |
thrombosis - diagnosis - etiology - surgery |
8 |
tissue donors - statistics & numerical data |
8 |
tki |
8 |
transcription factors - genetics - metabolism - physiology |
8 |
tyrosine-kinase inhibitor |
8 |
unresectable |
8 |
waiting list |
8 |
wedge resection |
8 |
abdominal abscess |
7 |
abdominal bleeding |
7 |
abdominal surgery |
7 |
activities of daily living |
7 |
adenine - analogs & derivatives - therapeutic use |
7 |
adiponectin |
7 |
adiponectin - blood - chemistry - genetics |
7 |
adiponectin oligomeric form |
7 |
adjuvant therapy |
7 |
alanine transaminase - blood |
7 |
american society of anaesthesiologists (asa) |
7 |
anastomosis, roux-en-y |
7 |
anastomosis, surgical |
7 |
anastomosis, surgical - methods |
7 |
anti-steatosis |
7 |
asia |
7 |
bile duct diseases - etiology |
7 |
bile ducts - blood supply - surgery |
7 |
biliary obstruction |
7 |
bone marrow transplantation |
7 |
cadaveric transplantation |
7 |
cap |
7 |
carcinoma, hepatocellular - blood supply - drug therapy - pathology |
7 |
carcinoma, hepatocellular - diagnosis - pathology - surgery |
7 |
carcinoma, hepatocellular - enzymology - genetics |
7 |
carcinoma, hepatocellular - genetics - metabolism - pathology - virology |
7 |
carcinoma, hepatocellular - mortality - pathology - therapy |
7 |
cardiac surgery |
7 |
catheter ablation |
7 |
catheters, indwelling |
7 |
cell differentiation |
7 |
cell survival signaling |
7 |
chemokine cxcl10 - metabolism |
7 |
child-pugh a |
7 |
children |
7 |
chinese |
7 |
cholecystitis, acute - surgery |
7 |
cholecystostomy - instrumentation - methods |
7 |
cholestasis - etiology |
7 |
chronic hepatitis b |
7 |
combined resection |
7 |
complication |
7 |
cytology and histology |
7 |
de novo hbv |
7 |
de novo hepatocellular carcinoma |
7 |
deceased-donor liver transplantation |
7 |
dna-binding proteins - metabolism |
7 |
domino liver transplant |
7 |
down-regulation |
7 |
drug resistance, viral - genetics |
7 |
endothelin-1 - genetics |
7 |
entecavir |
7 |
experience |
7 |
extended criteria organ |
7 |
fatty liver - pathology - surgery |
7 |
fty720 |
7 |
gene expression profiling |
7 |
graft rejection |
7 |
graft rejection - blood - drug therapy - pathology |
7 |
graft survival - drug effects |
7 |
graft-to-recipient weight ratio |
7 |
head of pancreas |
7 |
hepatic artery - surgery |
7 |
hepatic microcirculation |
7 |
hepatitis - surgery |
7 |
hepatitis b - complications |
7 |
hepatitis b - drug therapy - prevention & control - surgery |
7 |
hepatitis b vaccination |
7 |
hepatitis b virus - genetics |
7 |
hepatitis b, chronic - complications - drug therapy - pathology |
7 |
hepatocellular |
7 |
hepatocytes - cytology |
7 |
high-intensity focused ultrasound ablation - methods |
7 |
histocompatibility |
7 |
icc |
7 |
indocyanine green clearance |
7 |
informed consent |
7 |
kidney transplantation |
7 |
limon |
7 |
liver - metabolism |
7 |
liver biopsy |
7 |
liver cirrhosis - blood - metabolism - pathology - virology |
7 |
liver diseases - congenital - mortality - surgery |
7 |
liver diseases - epidemiology - surgery |
7 |
liver neoplasms - complications - surgery |
7 |
liver neoplasms - diagnosis - pathology - surgery |
7 |
liver neoplasms - enzymology - genetics |
7 |
liver neoplasms - genetics - metabolism - pathology - virology |
7 |
liver neoplasms - mortality - pathology - therapy |
7 |
liver neoplasms, experimental - blood supply - drug therapy - pathology |
7 |
liver transplantation - adverse effects - methods |
7 |
liver transplantation - adverse effects - methods - mortality |
7 |
liver transplantation - adverse effects - methods - pathology - statistics & numerical data |
7 |
liver transplantation - methods - physiology |
7 |
living donors - classification |
7 |
logistic models |
7 |
long-term survival |
7 |
macrophage |
7 |
mafld |
7 |
malignancy |
7 |
matrix metalloproteinase 9 - metabolism |
7 |
metabolic syndrome |
7 |
microsurgery |
7 |
microvascular anastomosis |
7 |
model for end-stage liver disease |
7 |
molecular weight |
7 |
nafld |
7 |
neovascularization, pathologic - drug therapy |
7 |
nitric oxide synthase - metabolism |
7 |
olt |
7 |
oncology medical sciences |
7 |
pegylated interferon alfa-2a |
7 |
percutaneous transhepatic cholecystostomy (ptc) |
7 |
phosphonic acids |
7 |
portal vein resection |
7 |
post-transplantation lymphoproliferative disease |
7 |
postoperative complications - prevention & control - surgery |
7 |
proline-rich tyrosine kinase2 (pyk2) |
7 |
ptbd |
7 |
pulse spectrophotometry |
7 |
radiology and nuclear medicine pharmacy and pharmacology biology |
7 |
rats, inbred lew |
7 |
recurrent hcc |
7 |
registries |
7 |
retransplantation |
7 |
right-lobe |
7 |
rna, messenger - metabolism |
7 |
sepsis - prevention & control |
7 |
small-for-size syndrome |
7 |
solid organ transplantation |
7 |
split graft liver transplant |
7 |
stat5 transcription factor - biosynthesis - genetics - metabolism |
7 |
stents |
7 |
survival outcomes |
7 |
sustained virological response |
7 |
systemic therapy |
7 |
thoracic surgery |
7 |
thrombosis - prevention & control |
7 |
transcription factors - metabolism |
7 |
transplantation |
7 |
transplantation, homologous |
7 |
transthyretin |
7 |
usg-guided |
7 |
val30ala |
7 |
vascular surgery |
7 |
vcte |
7 |
whipple operation |
7 |
acute kidney injury - surgery |
6 |
acute pancreatitis |
6 |
adefovir |
6 |
adrenal cortex hormones - administration & dosage |
6 |
akt signaling pathway |
6 |
angiogenesis |
6 |
angiopoietin-like 4 |
6 |
antibodies, monoclonal - administration & dosage - therapeutic use |
6 |
antigens, viral - blood |
6 |
antineoplastic agents - adverse effects - therapeutic use |
6 |
antineoplastic agents, hormonal - administration & dosage |
6 |
azathioprine - therapeutic use |
6 |
biliary reconstruction |
6 |
biliary stricture |
6 |
blotting, western |
6 |
bowel preparation |
6 |
breast cancer |
6 |
cancer |
6 |
cancer metabolism |
6 |
carcinoma, hepatocellular - complications - surgery |
6 |
carcinoma, hepatocellular - diagnosis - therapy |
6 |
carcinoma, hepatocellular - drug therapy - mortality |
6 |
carcinoma, hepatocellular - drug therapy - pathology - surgery - virology |
6 |
carcinoma, hepatocellular - epidemiology - surgery |
6 |
carcinoma, hepatocellular - genetics - metabolism - pathology |
6 |
carcinoma, hepatocellular - genetics - mortality - pathology - surgery - therapy |
6 |
carcinoma, hepatocellular - genetics - prevention and control - secondary |
6 |
case-matched study |
6 |
cd133 |
6 |
cd274 |
6 |
cdna microarray |
6 |
cell adhesion molecules |
6 |
cell cycle - genetics |
6 |
cell cycle proteins - genetics |
6 |
chemokines |
6 |
chemoresistance |
6 |
cholangiograms |
6 |
cisplatin |
6 |
close resection margin |
6 |
colorectal liver metastasis |
6 |
complex liver resection |
6 |
controlled study |
6 |
cyclin-dependent kinase inhibitor p21 |
6 |
cytokines |
6 |
cytomegalovirus - immunology |
6 |
daptomycin |
6 |
decolonization |
6 |
desmosplastic reaction |
6 |
diabetes mellitus - epidemiology - prevention & control |
6 |
diagnostic imaging |
6 |
dna, viral - blood |
6 |
donor hepatectomy |
6 |
duct-to-duct anastomosis |
6 |
ductal anomaly |
6 |
elderly |
6 |
en-bloc resection |
6 |
end-stage liver disease |
6 |
endoscopic retrograde cholangiography |
6 |
endoscopic treatment |
6 |
endothelin-1 - genetics - metabolism |
6 |
endothelium, vascular - pathology |
6 |
epithelial-mesenchymal transition |
6 |
erc |
6 |
extracellular signal-regulated map kinases - metabolism |
6 |
family history |
6 |
focal adhesion kinase |
6 |
gastrin |
6 |
gene expression |
6 |
gene expression regulation |
6 |
gene expression regulation - physiology |
6 |
genes, p53 - genetics |
6 |
glycolysis |
6 |
graft |
6 |
graft injury |
6 |
graft rejection - epidemiology - prevention & control |
6 |
graft-weight-to-recipient-weight ratio |
6 |
heme oxygenase (decyclizing) - genetics |
6 |
hepatic veins - surgery |
6 |
hepaticojejunostomy |
6 |
hepatitis b - prevention & control - surgery |
6 |
hepatitis b e antigens - blood |
6 |
hepatitis b surface antigens - analysis |
6 |
hepatitis b surface antigens - analysis - blood |
6 |
hepatitis b, chronic - mortality - surgery |
6 |
hepatocellular carcinomas |
6 |
hepatocellullar carconoma |
6 |
hepatocholangiocarcinoma |
6 |
hfe |
6 |
histone modifications |
6 |
homeodomain proteins - antagonists and inhibitors - genetics - metabolism |
6 |
homeodomain proteins - genetics - metabolism |
6 |
homeoprotein six1 |
6 |
hypertension, portal - etiology - physiopathology |
6 |
immunoglobulins - therapeutic use |
6 |
immunosuppressive agents - administration & dosage - therapeutic use |
6 |
inflammasomes |
6 |
inflammatory response |
6 |
inflow |
6 |
injections, intravenous |
6 |
interference |
6 |
interferon-alpha - adverse effects - therapeutic use |
6 |
intragraft gene expression profiles |
6 |
intrahepatic cholangiocarcinoma |
6 |
kc |
6 |
keywords |
6 |
kidney neoplasms - genetics - prevention and control - secondary |
6 |
lactobacillus rhamnosus gg |
6 |
ldlt |
6 |
ligation |
6 |
linezolid |
6 |
lipocalins |
6 |
liver - blood supply - metabolism - pathology - surgery |
6 |
liver - blood supply - pathology |
6 |
liver - pathology |
6 |
liver - pathology - ultrasonography |
6 |
liver neoplasms - blood supply - surgery - ultrastructure |
6 |
liver neoplasms - diagnosis - therapy |
6 |
liver neoplasms - drug therapy - mortality |
6 |
liver neoplasms - drug therapy - pathology - surgery - virology |
6 |
liver neoplasms - epidemiology - surgery |
6 |
liver neoplasms - genetics - metabolism - pathology |
6 |
liver neoplasms - genetics - mortality - pathology - surgery - therapy |
6 |
liver neoplasms, experimental - genetics - pathology - prevention and control |
6 |
liver neoplasms, experimental - metabolism - pathology - surgery |
6 |
liver resection (lr) |
6 |
liver transplantation (lt) |
6 |
liver transplantation - adverse effects - immunology |
6 |
liver transplantation - adverse effects - pathology - physiology |
6 |
liver transplantation - pathology |
6 |
liver transplantation - pathology - physiology |
6 |
liver transplantation - physiology |
6 |
liver transplantation - statistics and numerical data |
6 |
living |
6 |
lung neoplasms - etiology - metabolism - secondary |
6 |
m2 macrophages |
6 |
matrix stiffness |
6 |
mechanoepigenetics |
6 |
metastases |
6 |
mitochondria, liver - pathology |
6 |
modulation |
6 |
mycophenolic acid - administration & dosage - analogs & derivatives |
6 |
neoplasm recurrence, local - etiology - metabolism - pathology |
6 |
neuroendocrine carcinoma |
6 |
neutrophil |
6 |
nitric oxide synthase - genetics - metabolism |
6 |
nitric oxide synthase type iii |
6 |
nomogram |
6 |
octreotide - administration & dosage |
6 |
omeprazole |
6 |
p21/waf1 |
6 |
p53 |
6 |
pancreatic tumor |
6 |
pathologic tumour-node-metastasis (ptnm) stage |
6 |
pediatric donor |
6 |
pkm2 |
6 |
placebos |
6 |
polyethylene glycol |
6 |
polymerase chain reaction |
6 |
portal pressure - physiology |
6 |
post-lt surveillance |
6 |
post-transplant recurrence |
6 |
postoperative period |
6 |
prediction |
6 |
predictive model |
6 |
predictive value of tests |
6 |
primary transplantation |
6 |
prmt6 |
6 |
prognostic predictor |
6 |
progression |
6 |
proliferating cell nuclear antigen |
6 |
proliferating cell nuclear antigen - analysis |
6 |
propensity score matching |
6 |
radiofrequency ablation (rfa) |
6 |
rap1 |
6 |
receptors, interleukin-2 - immunology |
6 |
recombinant fusion proteins |
6 |
recurrent hepatocellular carcinoma |
6 |
regional blood flow - physiology |
6 |
reperfusion injury - pathology |
6 |
right liver donation |
6 |
right-liver |
6 |
risk factor |
6 |
risk factors |
6 |
rna, small interfering - pharmacology |
6 |
short hairpin rna (shrna) |
6 |
simultaneous resection |
6 |
six1 |
6 |
size |
6 |
small-for-size fatty liver |
6 |
small-for-size grafts |
6 |
stage resection |
6 |
standard |
6 |
synchronous colorectal liver metastasis |
6 |
tacrolimus - administration & dosage |
6 |
tacrolimus - therapeutic use |
6 |
thbs2 |
6 |
therapeutic |
6 |
tissue and organ procurement - organization & administration |
6 |
transplantation, isogeneic |
6 |
tuberculosis |
6 |
tumor suppressor gene |
6 |
tumour thrombus |
6 |
vancomycin-resistant enterococci |
6 |
venous infiltration |
6 |
waiting lists |
6 |
warburg effect |
6 |
zollinger-ellison syndrome |
6 |
acute-on-chronic liver failure |
5 |
acute-phase reaction |
5 |
acute-phase reaction - metabolism - pathology |
5 |
adenosine - chemistry |
5 |
adenosinergic signaling pathway |
5 |
adjuvant chemotherapy |
5 |
adoptive transfer |
5 |
adrenal cortex hormones - therapeutic use |
5 |
akt |
5 |
akt survival pathway |
5 |
alagille syndrome |
5 |
albumins - genetics - metabolism |
5 |
aldose reductase |
5 |
allopurinol - chemistry |
5 |
alpha-fetoprotein |
5 |
alpha-fetoprotein (afp) |
5 |
amino acid substitution |
5 |
amyloid neuropathies, familial - surgery |
5 |
amyloidosis, familial - ethnology - genetics - pathology |
5 |
analysis of variance |
5 |
angioplasty - methods |
5 |
animal models |
5 |
anterior approach |
5 |
antibody therapy |
5 |
antineoplastic agents, hormonal - therapeutic use |
5 |
antitubercular agents - pharmacokinetics - therapeutic use |
5 |
anxa3 |
5 |
apolipoprotein c-iii |
5 |
apolipoproteins c - metabolism |
5 |
asian continental ancestry group - genetics |
5 |
aspartate aminotransferase |
5 |
aspartate aminotransferases - blood |
5 |
augmented reality |
5 |
bile duct atresia |
5 |
bile duct obstruction |
5 |
bile duct reconstruction |
5 |
bile leakage |
5 |
biopsy |
5 |
biopsy, needle - adverse effects - methods |
5 |
blood loss, surgical - prevention & control |
5 |
blunt trauma |
5 |
bone marrow transplantation - adverse effects |
5 |
cancer cell culture |
5 |
cancer stem cells |
5 |
carcinoma - secondary - surgery |
5 |
carcinoma, hepatocellular |
5 |
carcinoma, hepatocellular - blood - blood supply - pathology |
5 |
carcinoma, hepatocellular - blood - diagnosis - surgery |
5 |
carcinoma, hepatocellular - chemistry - drug therapy - mortality |
5 |
carcinoma, hepatocellular - complications - diagnosis - surgery |
5 |
carcinoma, hepatocellular - complications - pathology - surgery |
5 |
carcinoma, hepatocellular - enzymology - pathology |
5 |
carcinoma, hepatocellular - enzymology - pathology - ultrastructure |
5 |
case-control studies |
5 |
cause of death |
5 |
ccaat-enhancer-binding proteins - physiology |
5 |
cell fusion |
5 |
cell movement - physiology |
5 |
cell-free circulating nucleic acid |
5 |
chemokine cxcl2 |
5 |
chemokines, cxc - metabolism |
5 |
chemosensitization |
5 |
chi-square distribution |
5 |
cholangiocarcinoma - complications - pathology - surgery |
5 |
cholangiopancreatography, endoscopic retrograde - adverse effects |
5 |
cholangiopancreatography, endoscopic retrograde - methods |
5 |
cholelithiasis - complications - diagnosis - surgery |
5 |
cholestasis, intrahepatic - drug therapy - etiology - surgery |
5 |
clinical competence |
5 |
clonorchis sinensis |
5 |
colorectal neoplasms - pathology |
5 |
complications |
5 |
computer systems |
5 |
confidence intervals |
5 |
cyclin d1 |
5 |
cytokines - blood - genetics |
5 |
deceased donor |
5 |
deceased-donor liver re-transplantation |
5 |
disease transmission, infectious |
5 |
dna - analysis |
5 |
dna primers - chemistry |
5 |
dna probes |
5 |
dna, viral - metabolism |
5 |
dna-binding proteins - physiology |
5 |
donor/recipient origin |
5 |
double bypass |
5 |
down-regulation - drug effects |
5 |
dual portal vein |
5 |
early growth response protein 1 |
5 |
emergency medical services |
5 |
endosonography |
5 |
endothelial growth factors - blood |
5 |
endothelin-1 - blood - genetics |
5 |
endothelin-1 - metabolism |
5 |
energy metabolism - drug effects - physiology |
5 |
entpd1/cd39 |
5 |
enzyme activity |
5 |
epidermal growth factor - metabolism |
5 |
epithelial-mesenchymal transition - physiology |
5 |
et5e/cd73 |
5 |
evaluation studies as topic |
5 |
extracellular adenosine |
5 |
familial transthyretin amyloidosis |
5 |
fibrosis - drug therapy - pathology |
5 |
focal adhesion kinase 2 - metabolism - physiology |
5 |
gallstones - complications - ultrasonography |
5 |
glucagon - blood |
5 |
glutathione - chemistry |
5 |
glycogen synthase kinase 3 - metabolism |
5 |
graft failure |
5 |
graft rejection - drug therapy |
5 |
graft survival - drug effects - genetics |
5 |
graft survival - drug effects - immunology - physiology |
5 |
graft survival - physiology |
5 |
grp78 |
5 |
heme oxygenase (decyclizing) - biosynthesis |
5 |
hepatectomy - classification - methods |
5 |
hepatic artery thrombosis |
5 |
hepatic ischemia reperfusion injury |
5 |
hepatic malignancy |
5 |
hepatic resection |
5 |
hepatic senescence |
5 |
hepatic steatosis |
5 |
hepatic stellate cell (hsc) |
5 |
hepatic stellate cells |
5 |
hepatic veins - physiopathology - surgery |
5 |
hepatitis b - complications - drug therapy - surgery |
5 |
hepatitis b - complications - etiology |
5 |
hepatitis b antibodies - blood |
5 |
hepatitis b core antigens - genetics |
5 |
hepatitis b surface antigens - immunology |
5 |
hepatitis b virus |
5 |
hepatitis b, chronic - immunology - surgery |
5 |
hepatitis b, chronic - surgery |
5 |
hepatology |
5 |
hepatopancreatoduodenectomy |
5 |
hong kong chinese |
5 |
hsp70 heat-shock proteins - genetics |
5 |
hsp70 heat-shock proteins - metabolism |
5 |
hypertension - epidemiology |
5 |
hypertension, portal - etiology - prevention & control |
5 |
hypertension, portal - mortality - physiopathology - surgery |
5 |
hypoglycemic agents - pharmacology |
5 |
hypoxia |
5 |
iatrogenic disease |
5 |
immediate-early proteins |
5 |
immediate-early proteins - metabolism |
5 |
immunosuppressive agents - administration and dosage |
5 |
immunosuppressive agents - pharmacology |
5 |
in situ hybridization, fluorescence |
5 |
in situ nick-end labeling |
5 |
insulin - chemistry - pharmacology |
5 |
insulin receptor substrate proteins |
5 |
intercellular signaling peptides and proteins - metabolism |
5 |
interleukin-10 - biosynthesis |
5 |
internal medicine |
5 |
intracellular signaling peptides and proteins |
5 |
intraoperative complications |
5 |
ir injury |
5 |
kaplan-meier estimate |
5 |
ketone bodies - blood |
5 |
lamivudine - administration and dosage |
5 |
laparoscopic hepatectomy |
5 |
leukemia, myelogenous, chronic, bcr-abl positive - therapy |
5 |
live donor liver transplantation |
5 |
liver - anatomy & histology |
5 |
liver - anatomy & histology - drug effects - ultrastructure |
5 |
liver - anatomy & histology - pathology - physiopathology |
5 |
liver - anatomy and histology |
5 |
liver - drug effects - injuries - metabolism |
5 |
liver - metabolism - ultrastructure |
5 |
liver - physiology - surgery |
5 |
liver - radiography |
5 |
liver cell carcinoma |
5 |
liver cirrhosis - complications |
5 |
liver cirrhosis - complications - virology |
5 |
liver cirrhosis - drug therapy - etiology - surgery |
5 |
liver cirrhosis, experimental - surgery |
5 |
liver laceration |
5 |
liver neoplasms - blood - blood supply - pathology |
5 |
liver neoplasms - blood - diagnosis - surgery |
5 |
liver neoplasms - blood - secondary - surgery |
5 |
liver neoplasms - blood - surgery |
5 |
liver neoplasms - chemistry - drug therapy - mortality |
5 |
liver neoplasms - complications - diagnosis - surgery |
5 |
liver neoplasms - complications - pathology - surgery |
5 |
liver neoplasms - diagnosis - etiology - genetics - surgery |
5 |
liver neoplasms - enzymology - pathology |
5 |
liver neoplasms - enzymology - pathology - ultrastructure |
5 |
liver neoplasms - therapy |
5 |
liver remnant |
5 |
liver transplantation - adverse effects - mortality |
5 |
liver transplantation - immunology - methods - physiology |
5 |
liver transplantation - immunology - mortality - physiology |
5 |
liver transplantation - methods - mortality |
5 |
liver transplantation - methods - mortality - statistics & numerical data |
5 |
liver transplantation - methods - pathology |
5 |
liver transplantation - mortality - physiology - statistics & numerical data |
5 |
liver trauma |
5 |
living related donor |
5 |
living-donor liver re-transplantation |
5 |
lobectomy |
5 |
longitudinal studies |
5 |
lymphatic metastasis |
5 |
lymphocytes - immunology |
5 |
lymphokines - blood |
5 |
lymphoma, b-cell - etiology - genetics - pathology |
5 |
map kinase signaling system |
5 |
map kinase signaling system - drug effects - physiology |
5 |
mapk |
5 |
marrow transplantation |
5 |
matrix metalloproteinase-12 |
5 |
medical errors - adverse effects |
5 |
meld score biliary atresia |
5 |
meta-analysis |
5 |
metachronous primary hcc |
5 |
metal stent |
5 |
microsatellite analysis |
5 |
microsatellite repeats |
5 |
models, animal |
5 |
momp |
5 |
multidrug resistance protein 1 |
5 |
multiple injuries |
5 |
mutant |
5 |
mutation |
5 |
neoplasm invasiveness |
5 |
neoplasm recurrence, local - blood - diagnosis |
5 |
neoplasm recurrence, local - mortality |
5 |
neoplasm recurrence, local - mortality - pathology |
5 |
neoplasm seeding |
5 |
neoplasms, second primary - mortality - surgery |
5 |
neovascularization, pathologic |
5 |
neutrophils |
5 |
neutrophils migration |
5 |
nf-kappa b - metabolism |
5 |
nf-κb signaling |
5 |
non-operative management |
5 |
nuclear factor-κb |
5 |
nuclear family |
5 |
oligonucleotide array sequence analysis |
5 |
oncological outcomes |
5 |
opportunistic infections - prevention and control |
5 |
organ preservation |
5 |
organ preservation solutions - chemistry |
5 |
organ transplantation - adverse effects - pathology |
5 |
overall survival |
5 |
oxygenation |
5 |
oxylab po2 |
5 |
p38 mitogen-activated protein kinases - metabolism |
5 |
palliative care - methods |
5 |
pancreatic cancer |
5 |
pancreaticojejunostomy |
5 |
pancreatitis - etiology - ultrasonography |
5 |
pancreatitis, acute necrotizing - diagnosis - etiology - surgery |
5 |
pancreatoduodenectomy |
5 |
peld score |
5 |
penetrative trauma |
5 |
phosphoproteins - physiology |
5 |
plasma mrna |
5 |
platelet count |
5 |
portal vein - anatomy and histology - surgery |
5 |
portal vein - physiopathology - surgery |
5 |
portal vein reconstruction |
5 |
post-hepatectomy |
5 |
post-operative complication |
5 |
post-transplantation lymphoproliferative disorder |
5 |
postoperative complications - etiology |
5 |
postoperative complications - etiology - pathology |
5 |
prealbumin - genetics |
5 |
predicting scoring system |
5 |
prediction model |
5 |
preoperative care - methods |
5 |
probability |
5 |
proctology |
5 |
promoter regions, genetic - genetics |
5 |
prophylaxis |
5 |
propylene glycols - pharmacology |
5 |
propylene glycols - therapeutic use |
5 |
protein-serine-threonine kinases - physiology |
5 |
protein-tyrosine kinases - physiology |
5 |
proteins - genetics |
5 |
proteins - metabolism |
5 |
proto-oncogene proteins - physiology |
5 |
proto-oncogene proteins c-akt |
5 |
raf kinases - metabolism |
5 |
raffinose - chemistry |
5 |
receptors, endothelin - genetics |
5 |
receptors, estrogen - analysis |
5 |
receptors, progesterone - analysis |
5 |
reconstructive surgical procedures - methods |
5 |
reference values |
5 |
referral and consultation |
5 |
regorafenib |
5 |
regulatory t cells |
5 |
remnant |
5 |
reperfusion injury - drug therapy |
5 |
reperfusion injury - metabolism - physiopathology |
5 |
right lobe graft |
5 |
risk assessment |
5 |
rna, messenger - analysis |
5 |
rna, messenger - blood |
5 |
rupture - etiology - mortality - pathology |
5 |
sarcoma - diagnosis - etiology - genetics - surgery |
5 |
segmentectomy |
5 |
serum albumin - analysis |
5 |
signal transduction |
5 |
signal transduction - drug effects - physiology |
5 |
single-blind method |
5 |
sirolimus - administration and dosage |
5 |
smad inhibitor |
5 |
smad2/3/smad4 |
5 |
small-for-size graft |
5 |
somatostatin - therapeutic use |
5 |
sorafenib resistance |
5 |
sphingosine - analogs & derivatives |
5 |
statistics, nonparametric |
5 |
stem cell |
5 |
steroids - therapeutic use |
5 |
sterol regulatory element binding protein 1 |
5 |
stress, mechanical |
5 |
survival rate - trends |
5 |
t cell exhaustion |
5 |
tace |
5 |
tamoxifen - therapeutic use |
5 |
tissue and organ harvesting - methods |
5 |
tissue donors - supply & distribution |
5 |
toce |
5 |
tomography, x-ray computed |
5 |
transcription factors - physiology |
5 |
transferrin - analysis |
5 |
transplantation, homologous - adverse effects |
5 |
ttr gene |
5 |
tuberculosis - diagnosis - drug therapy - transmission |
5 |
tumor-initiating cell |
5 |
up-regulation |
5 |
up-regulation - physiology |
5 |
upr pathway |
5 |
vascular endothelial growth factor a |
5 |
vascular endothelial growth factors |
5 |
vasoconstriction - physiology |
5 |
" surrogate" end point |
4 |
78-kda glucose-regulated protein |
4 |
abo blood-group system - immunology |
4 |
active immunization |
4 |
acute rejection |
4 |
adenine - analogs and derivatives - therapeutic use |
4 |
adenosine |
4 |
afp |
4 |
allopurinol |
4 |
alpha-fetoproteins - analysis |
4 |
anastomosis, surgical - adverse effects |
4 |
antibody against hepatitis b surface antigen |
4 |
antibody formation |
4 |
antibody-mediated rejection |
4 |
apoa-1 |
4 |
associating liver partition and portal vein ligation for staged hepatectomy |
4 |
biliary tract neoplasms - complications - mortality |
4 |
bilirubin level |
4 |
biomaterial |
4 |
biomedical research |
4 |
blood group incompatibility - immunology |
4 |
blood loss, surgical - statistics & numerical data |
4 |
blood vessel prosthesis implantation |
4 |
bone marrow cells - pathology |
4 |
bregs |
4 |
carcinoma, hepatocellular - complications - mortality - surgery |
4 |
carcinoma, hepatocellular - diagnosis - etiology - surgery |
4 |
carcinoma, hepatocellular - diagnosis - surgery |
4 |
carcinoma, hepatocellular - epidemiology - etiology - pathology |
4 |
carcinoma, hepatocellular - mortality |
4 |
carcinoma, hepatocellular - mortality - therapy |
4 |
carcinoma, hepatocellular - pathology - surgery - virology |
4 |
carcinoma, hepatocellular - therapy |
4 |
caspase |
4 |
caspase 3 |
4 |
cell cycle checkpoint |
4 |
chemoembolization |
4 |
chemoembolization, therapeutic |
4 |
chemotherapy |
4 |
china |
4 |
cholangiocarcinoma - pathology - surgery |
4 |
cholangiopancreatography, endoscopic retrograde - methods - mortality |
4 |
cholangitis - etiology - surgery |
4 |
cholangitis - mortality - therapy |
4 |
choledochostomy |
4 |
cholestasis - etiology - surgery |
4 |
cholestasis - mortality - surgery - therapy |
4 |
cholestasis - surgery |
4 |
cholesterol |
4 |
chromosomes, human, y |
4 |
clinical outcomes |
4 |
combined hcc-cc |
4 |
complement component |
4 |
complex liver surgery |
4 |
contraceptives, oral - administration & dosage |
4 |
cytokine receptor gp130 - metabolism |
4 |
cytotoxicity |
4 |
diagnosis prediction |
4 |
discriminant analysis |
4 |
dna, viral - analysis |
4 |
drainage |
4 |
drug reaction |
4 |
drug-induced liver injury - etiology - metabolism - pathology - surgery |
4 |
dual graft |
4 |
dyslipidemia |
4 |
early-phase |
4 |
embryonic liver |
4 |
emergency laparoscopic cholecystectomy |
4 |
end stage liver disease - surgery - virology |
4 |
ercp |
4 |
family practice - trends |
4 |
fasting glucose |
4 |
fatal outcome |
4 |
fatty change |
4 |
fatty liver - pathology - radiography |
4 |
female patient |
4 |
fibrosis progression |
4 |
fish |
4 |
fluorescent antibody technique |
4 |
forecasting |
4 |
gallbladder |
4 |
gender |
4 |
glutathione |
4 |
gore-tex graft |
4 |
graft occlusion, vascular - diagnosis - etiology - physiopathology - surgery |
4 |
graft survival - drug effects - physiology |
4 |
graft survival - immunology |
4 |
graft vs host disease - diagnosis - etiology - pathology |
4 |
grafts |
4 |
granulin-epithelin precursor |
4 |
hbv |
4 |
hcc invasiveness |
4 |
hcc recurrence |
4 |
hemoglobin-based oxygen carrier |
4 |
hemostasis, surgical |
4 |
hepatectom |
4 |
hepatectomy - adverse effects - contraindications - methods - mortality |
4 |
hepatectomy - adverse effects - methods |
4 |
hepatectomy - adverse effects - methods - mortality |
4 |
hepatectomy - adverse effects - mortality - standards |
4 |
hepatectomy - statistics and numerical data |
4 |
hepatic bipotent cells |
4 |
hepatic ischemia reperfusion |
4 |
hepatic veins - physiopathology |
4 |
hepatic veins - physiopathology - radiography - surgery |
4 |
hepatitis |
4 |
hepatitis b - complications - pathology - surgery |
4 |
hepatitis b - prevention & control - surgery - therapy |
4 |
hepatitis b antibodies - analysis |
4 |
hepatitis b e antigens - analysis |
4 |
hepatitis b immune globulin |
4 |
hepatitis b vaccines - therapeutic use |
4 |
hepatitis b virus - genetics - immunology |
4 |
hepatitis b, chronic - drug therapy - pathology - virology |
4 |
hepatitis b, chronic - etiology - immunology - prevention & control |
4 |
hepatitis, chronic - complications - surgery |
4 |
hepatocytes - metabolism - pathology - transplantation |
4 |
hepatopancreaticobiliary surgery |
4 |
hernia - etiology |
4 |
high intensity focused ultrasound |
4 |
hilar cholangiocarcinoma |
4 |
histocompatibility testing |
4 |
histology |
4 |
hla |
4 |
hla antigens - analysis |
4 |
hsp70 heat-shock proteins - genetics - metabolism |
4 |
hydroge |
4 |
icg fluorescence |
4 |
imaging |
4 |
immunity |
4 |
immunization |
4 |
indocyanine green |
4 |
indocyanine green - diagnostic use |
4 |
inflammasome |
4 |
inflammatory responses |
4 |
inoperable |
4 |
insulin - pharmacology |
4 |
interferon-gamma |
4 |
interleukin-6 - genetics - metabolism |
4 |
internal hernia |
4 |
interventional radiology |
4 |
intestinal diseases - etiology - surgery |
4 |
intestinal obstruction |
4 |
intestinal obstruction - etiology - surgery |
4 |
intravital imaging |
4 |
ionizing radiation |
4 |
ischemic injury |
4 |
kupffer cells - cytology |
4 |
laparoscopic ultrasonography |
4 |
laparoscopy - statistics and numerical data |
4 |
left lobe graft |
4 |
lipid metabolism |
4 |
lipoprotein |
4 |
live donor |
4 |
liver - drug effects - pathology |
4 |
liver - metabolism - pathology |
4 |
liver - pathology - radiography - surgery |
4 |
liver circulation |
4 |
liver circulation - drug effects |
4 |
liver cirrhosis - complications - surgery |
4 |
liver cirrhosis - diagnosis - surgery |
4 |
liver cirrhosis - epidemiology - etiology - pathology |
4 |
liver complications |
4 |
liver graft |
4 |
liver neoplasms - complications - mortality - surgery |
4 |
liver neoplasms - diagnosis - etiology - surgery |
4 |
liver neoplasms - diagnosis - surgery |
4 |
liver neoplasms - epidemiology - etiology - pathology |
4 |
liver neoplasms - metabolism - pathology - surgery |
4 |
liver neoplasms - mortality |
4 |
liver neoplasms - mortality - therapy |
4 |
liver neoplasms - pathology - surgery - virology |
4 |
liver neoplasms - surgery - therapy |
4 |
liver regeneration |
4 |
liver steatosis |
4 |
liver transplantation - immunology - methods |
4 |
liver tumor |
4 |
living donor transplantation |
4 |
living donors - psychology - supply and distribution |
4 |
lliver neoplasms |
4 |
lymphocytes - pathology |
4 |
macrophage activation |
4 |
macrophages - cytology |
4 |
mass spectrometry |
4 |
mdsc |
4 |
member d |
4 |
mhc class i chain-related molecule a |
4 |
mir-1246 |
4 |
mixed tumor, malignant - pathology - surgery |
4 |
modified hai score |
4 |
natural-killer group 2 |
4 |
nf-κb |
4 |
notch signaling |
4 |
occult hbv co-infection |
4 |
oncology |
4 |
open conversion |
4 |
open liver resection |
4 |
organ preservation - methods |
4 |
organ preservation solutions |
4 |
pancreatic neoplasms - complications |
4 |
parenteral nutrition |
4 |
pattern |
4 |
pediatric |
4 |
perforin |
4 |
phlebography - methods |
4 |
phosphonic acids - therapeutic use |
4 |
pi3-kinase/akt |
4 |
pneumocystis jirovecii |
4 |
pneumocystis pneumonia |
4 |
post-liver transplant |
4 |
postoperative complications - epidemiology - mortality |
4 |
postoperative cytokines |
4 |
preoperative biliary drainage |
4 |
preventive medicine - methods |
4 |
primary biliary cirrhosis |
4 |
pringle manoeuvre |
4 |
protein interaction |
4 |
radiofrequency |
4 |
radiosurgery |
4 |
raffinose |
4 |
recurrence - prevention & control |
4 |
recurrent chronic hepatitis c virus |
4 |
relapsed infection due to hbv |
4 |
reperfusion injury - physiopathology |
4 |
resectability |
4 |
response marker |
4 |
retreatment |
4 |
review |
4 |
right lobe |
4 |
ruptured hepatocellular carcinoma |
4 |
safety |
4 |
sepsis |
4 |
severe fibrosis |
4 |
single institution |
4 |
skin - pathology |
4 |
small for size liver graft |
4 |
small-for size graft |
4 |
small-for-size fatty graft injury |
4 |
split graft |
4 |
steatotic donor |
4 |
steatotic liver graft |
4 |
stress |
4 |
surgical procedures, operative |
4 |
survivor |
4 |
tacrolimus |
4 |
technique |
4 |
therapeutic potential |
4 |
therapeutic target |
4 |
thermal ablation |
4 |
tissue and organ harvesting - adverse effects - methods |
4 |
tissue and organ harvesting - adverse effects - mortality - standards |
4 |
transmembrane protein 47 |
4 |
transplant outcomes |
4 |
transplant research |
4 |
transplantation chimera |
4 |
transplants |
4 |
triglyceride |
4 |
tumor necrosis factor-alpha - genetics - metabolism |
4 |
tumor-suppressive protein |
4 |
tumour recurrence |
4 |
ultrastructure |
4 |
urology and nephrology |
4 |
vascular reconstruction |
4 |
vascular resection |
4 |
vein graft |
4 |
vena cava, inferior - surgery |
4 |
y chromosome - genetics |
4 |
adenosine - pharmacology |
3 |
adoptive immunity transfer |
3 |
alemtuzumab |
3 |
alternative splicing events |
3 |
aminopyrine - diagnostic use |
3 |
aminopyrine breath test |
3 |
amyloidosis |
3 |
antineoplastic agents - therapeutic use |
3 |
bacterial infections |
3 |
belatacept |
3 |
bias (epidemiology) |
3 |
bile |
3 |
bile ducts - metabolism - surgery |
3 |
bile ducts - pathology - surgery |
3 |
bile ducts, intrahepatic |
3 |
bile ducts, intrahepatic - pathology |
3 |
bile ducts, intrahepatic - surgery |
3 |
biliary tract - abnormalities - radiography |
3 |
biliary tract diseases |
3 |
biliary tract diseases - etiology |
3 |
biliary tract diseases - etiology - therapy |
3 |
biliary tract neoplasms - therapy |
3 |
biliary tract surgical procedures - adverse effects |
3 |
bleeding |
3 |
blood glucose - analysis |
3 |
blood loss, surgical - physiopathology |
3 |
blood transfusion, autologous |
3 |
body surface area |
3 |
breath tests |
3 |
calcineurin inhibitor |
3 |
calcium - diagnostic use |
3 |
cancer hallmarks |
3 |
carcinoma, hepatocellular - drug therapy - genetics - mortality |
3 |
carcinoma, hepatocellular - drug therapy - pathology - surgery |
3 |
carcinoma, hepatocellular - pathology - surgery - ultrasonography |
3 |
catheterization, central venous |
3 |
cell delivery |
3 |
central bisectionectomy |
3 |
chemotherapy, adjuvant |
3 |
chilaiditi's sign |
3 |
cholangiography |
3 |
cholangiopancreatography, endoscopic retrograde |
3 |
cholangitis |
3 |
cholangitis-therapy |
3 |
cholecystectomy, laparoscopic - adverse effects |
3 |
cholecystitis - surgery - ultrasonography |
3 |
cholelithiasis - diagnosis - therapy |
3 |
cholelithiasis - surgery - therapy |
3 |
cholestasis - epidemiology - metabolism - surgery |
3 |
cholestasis - physiopathology - surgery |
3 |
cisplatin - administration & dosage |
3 |
cisplatin resistance |
3 |
clinical trials as topic |
3 |
colon - radiography |
3 |
combined |
3 |
constriction, pathologic |
3 |
corticosteroid |
3 |
cost-benefit analysis |
3 |
cyclosporine |
3 |
deceased-donor |
3 |
dendritic cells - pathology |
3 |
diagnosis, differential |
3 |
diaphragm - radiography |
3 |
distal pancreatectomy |
3 |
double-blind method |
3 |
drainage-methods |
3 |
embolization, therapeutic |
3 |
embolization, therapeutic - methods |
3 |
endoscopy,-gastrointestinal |
3 |
enucleation |
3 |
epcs |
3 |
epidemiologic factors |
3 |
erectile dysfunction |
3 |
estimated standard liver weight |
3 |
everolimus |
3 |
fibrosis |
3 |
flexible endoscopy |
3 |
flowmetry |
3 |
follicular dendritic cell |
3 |
fulminant hepatic failure |
3 |
gallstones-surgery |
3 |
glucose - pharmacology |
3 |
graft shortage |
3 |
hbv vaccination |
3 |
hcv |
3 |
heart |
3 |
hepatic |
3 |
hepatic duct, common - pathology |
3 |
hepatic duct, common - surgery |
3 |
hepatic i/r injury |
3 |
hepatic ischemia/reperfusion |
3 |
hepatic veins |
3 |
hepatic veins - transplantation |
3 |
hepatitis, chronic - pathology - surgery |
3 |
hepatobiliary |
3 |
hepatocellular cancer |
3 |
hepatolithiasis |
3 |
hormones - administration & dosage |
3 |
hyperalimentation |
3 |
hypogonadism |
3 |
icg |
3 |
immunoglobulin |
3 |
immunology |
3 |
in vivo applications |
3 |
indocyanine green retention |
3 |
inferior vena cava |
3 |
inflammatory pseudotumour |
3 |
inflow control |
3 |
insulin - blood |
3 |
insulinoma - diagnosis - surgery |
3 |
intensity |
3 |
intensive care |
3 |
interferon-alpha - therapeutic use |
3 |
interventional endoscopy |
3 |
intestinal perforation - radiography |
3 |
intraoperative complications - etiology |
3 |
intraoperative complications - etiology - prevention & control |
3 |
ip10 |
3 |
jejunostomy - methods |
3 |
laparoscopic surgery |
3 |
laparotomy |
3 |
leiomyosarcoma |
3 |
linear models |
3 |
liver - blood supply |
3 |
liver - blood supply - surgery |
3 |
liver - surgery |
3 |
liver cirrhosis - pathology - surgery |
3 |
liver failure - etiology |
3 |
liver failure - radiography |
3 |
liver failure - surgery - therapy |
3 |
liver neoplasm |
3 |
liver neoplasms |
3 |
liver neoplasms - drug therapy - genetics - mortality |
3 |
liver neoplasms - drug therapy - pathology - surgery |
3 |
liver neoplasms - pathology - radiography - surgery |
3 |
liver neoplasms - pathology - surgery - ultrasonography |
3 |
liver regeneration - physiology |
3 |
liver transplantation - contraindications - methods |
3 |
liver transplantation - immunology - methods - mortality |
3 |
liver transplantation - methods - psychology |
3 |
liver transplantation using steatotic graft |
3 |
living donation |
3 |
living donors - psychology |
3 |
living-related liver donors |
3 |
lymphoma, follicular - pathology - radiography - surgery |
3 |
macrophage activation - immunology |
3 |
macrophages - immunology |
3 |
magnet‐driven |
3 |
metabolism and immune cells |
3 |
microrobots |
3 |
microvascular surgery |
3 |
mtor inhibitor |
3 |
multiple endocrine neoplasia type 1 - surgery |
3 |
mycophenolate |
3 |
non-colorectal liver metastasis |
3 |
nutritional support |
3 |
obstructive jaundice |
3 |
organ donation |
3 |
organ preservation solutions - pharmacology |
3 |
pancreatic insulinoma |
3 |
pancreatic neoplasms - diagnosis - surgery |
3 |
pancreatic pseudocyst - diagnosis |
3 |
pancreatitis - blood - etiology - prevention & control |
3 |
pancreatitis - blood - mortality |
3 |
pancreatitis-surgery |
3 |
photoacoustic imaging |
3 |
platelet apheresis |
3 |
portal inflow |
3 |
portal vein thrombosis |
3 |
portoenterostomy |
3 |
postoperative complications - epidemiology - prevention & control |
3 |
postoperative complications - etiology - therapy |
3 |
postoperative complications - radiography - therapy |
3 |
potassium chloride - pharmacology |
3 |
pregnancy |
3 |
quality of life |
3 |
questionnaires |
3 |
raffinose - pharmacology |
3 |
rapamycin |
3 |
regional blood flow/physiology |
3 |
regression analysis |
3 |
renal veins - surgery - ultrasonography |
3 |
resection margin |
3 |
right liver |
3 |
saphenous vein - surgery |
3 |
sequential |
3 |
sex factors |
3 |
sexual dysfunction |
3 |
simplifying |
3 |
sirolimus |
3 |
soft tissue sarcoma |
3 |
somatostatin - administration & dosage |
3 |
sotrastaurin |
3 |
sphincterotomy, endoscopic - adverse effects - mortality - statistics & numerical data |
3 |
sphincterotomy,-endoscopic-adverse-effects |
3 |
sphincterotomy,-endoscopic-mortality |
3 |
splanchnic circulation - physiology |
3 |
splenic artery |
3 |
splenic vein - surgery - ultrasonography |
3 |
spouses |
3 |
subclavian vein - surgery |
3 |
subphrenic abscess - radiography |
3 |
surgical approaches |
3 |
surgical procedures, elective |
3 |
t lymphocyte function |
3 |
tenofovir |
3 |
thrombocytosis |
3 |
tissue and organ harvesting |
3 |
tissue and organ procurement - methods |
3 |
tissue and organ procurement - statistics and numerical data |
3 |
tissue donors - supply and distributionhttp://hub.hku.hk/tools/edit-item |
3 |
tofacitinib |
3 |
transplantation, liver |
3 |
transplants - standards |
3 |
treg |
3 |
tregs |
3 |
tumor metastasis |
3 |
ultrasonography, interventional |
3 |
urea - blood |
3 |
vascular endothelial growth factor a - biosynthesis - immunology |
3 |
vascular endothelial growth factor receptor-2 - biosynthesis - immunology |
3 |
vena caval tumor |
3 |
venoplasty |
3 |
viral infections |
3 |
voclosporin |
3 |
yq23 |
3 |
abo blood-group system - adverse effects |
2 |
adenocarcinoma - secondary - surgery |
2 |
advanced hepatocellular carcinoma |
2 |
alkaline phosphatase - blood |
2 |
anastomosis, roux-en-y - standards |
2 |
anemia, hemolytic - etiology |
2 |
asian continental ancestry group |
2 |
bile duct |
2 |
bile duct neoplasms - radiography - surgery |
2 |
bile duct stricture |
2 |
bile ducts -- surgery. |
2 |
biliary complication |
2 |
biliary tract surgical procedures - standards |
2 |
blood banks |
2 |
blood grouping and crossmatching |
2 |
bloodless liver resection |
2 |
carcinoma, hepatocellular - blood |
2 |
carcinoma, hepatocellular - drug therapy - metabolism - pathology |
2 |
carcinoma, squamous cell - secondary - surgery |
2 |
cardia |
2 |
chimerism |
2 |
cholangiopancreatography, endoscopic retrograde - adverse effects - mortality |
2 |
choledocholithiasis |
2 |
covalently closed circular dna |
2 |
de-novo hepatitis b virus infection |
2 |
dna |
2 |
drain |
2 |
end-stage liver diseases |
2 |
endoscopic retrograde cholangiopancreatography |
2 |
endoscopy |
2 |
epoprostenol - administration & dosage |
2 |
erythrocytes - immunology |
2 |
esophageal neoplasms - surgery |
2 |
estimated standard liver volume |
2 |
expanded criteria |
2 |
exploration |
2 |
extended right lobe graft |
2 |
gallstones - radiography - therapy |
2 |
gamma-glutamyltransferase - blood |
2 |
graft rejection - immunology |
2 |
graft vs host disease - etiology |
2 |
hematopoietic stem cells - immunology |
2 |
heparanase |
2 |
hepatic duct, common - radiography - surgery |
2 |
hepatic injury |
2 |
hepatic venous outflow obstruction |
2 |
hepatitis b - surgery - therapy |
2 |
hepatitis b core antigen |
2 |
hepatitis b surface antigen |
2 |
hepatitis c virus |
2 |
hepatocellular cacinoma |
2 |
hepatocellular carcinoma metastasis |
2 |
hernia |
2 |
hilar plate |
2 |
history, 20th century |
2 |
inguinal |
2 |
insulinoma |
2 |
international cooperation |
2 |
isoantibodies - blood |
2 |
klatskin's tumor - radiography - surgery |
2 |
laparoscopic |
2 |
laparoscopic exploration of common bile duct |
2 |
laparotomy - adverse effects |
2 |
lithotripsy - methods |
2 |
liver - transplantation - china - hong kong. |
2 |
liver - transplantation. |
2 |
liver -- surgery. |
2 |
liver / transplantation |
2 |
liver metastases |
2 |
liver neoplasms - drug therapy - metabolism - pathology |
2 |
liver neoplasms - secondary |
2 |
liver transection |
2 |
liver transplantation - ethnology - immunology |
2 |
liver transplantation - history - methods |
2 |
liver transplantation - history - methods - trends |
2 |
liver tumour |
2 |
living donors - history |
2 |
localization |
2 |
loco-regional therapy |
2 |
lung neoplasms - drug therapy - metabolism - secondary |
2 |
matrix metallopeptidase |
2 |
mif |
2 |
mrecist |
2 |
neuroendocrine tumor |
2 |
oesophagus |
2 |
organ donors |
2 |
pancreatitis |
2 |
percutaneous transhepatic biliary drainage |
2 |
peritoneal neoplasms - secondary |
2 |
plasmapheresis |
2 |
postoperative complications - etiology - mortality - surgery |
2 |
ppar gamma - agonists - metabolism |
2 |
pparg |
2 |
pregnancy complications - surgery |
2 |
prophylactic therapy |
2 |
purpura, thrombotic thrombocytopenic - blood - chemically induced |
2 |
resection strategy |
2 |
right lobe living donor liver transplantation |
2 |
salvage therapy |
2 |
seroepidemiologic studies |
2 |
seroma |
2 |
small for size syndrome |
2 |
split liver transplantation |
2 |
stents - adverse effects |
2 |
stomach neoplasms - surgery |
2 |
surgical resection |
2 |
syndrome |
2 |
tacrolimus - administration & dosage - adverse effects |
2 |
thiazolidinediones - pharmacology |
2 |
thrombocytopenia - etiology |
2 |
tissue inhibitors of metalloproteinase |
2 |
treatment |
2 |
trisectionectomy |
2 |
ttp |
2 |
ultrasonography |
2 |
abo blood-group system |
1 |
alpha-fetoproteins - metabolism |
1 |
antibody formation - immunology |
1 |
arteriovenous malformations - diagnosis - radiography - surgery |
1 |
blood group incompatibility |
1 |
calcineurin - antagonists and inhibitors |
1 |
carcinoma, hepatocellular - blood - surgery |
1 |
causes |
1 |
cholecystectomy, laparoscopic |
1 |
cholelithiasis - surgery |
1 |
clinical manifestations |
1 |
covid-19 |
1 |
data collection |
1 |
diagnostic errors |
1 |
emergency surgery |
1 |
far east |
1 |
fatty liver - diagnosis |
1 |
filtration efficiency |
1 |
global |
1 |
graft rejection - blood |
1 |
graft rejection - epidemiology |
1 |
graft rejection - prevention and control |
1 |
health surveys |
1 |
hepatectomy - mortality |
1 |
hepatic artery |
1 |
hepatitis - diagnosis |
1 |
hepatitis b - complications - immunology |
1 |
hepatitis b - diagnosis - immunology - mortality |
1 |
hepatitis b - immunology |
1 |
hepatitis b vaccines - immunology |
1 |
home-made masks |
1 |
immunity, cellular - immunology |
1 |
liver - cancer - treatment. |
1 |
liver cirrhosis - etiology - surgery |
1 |
liver failure, acute - therapy |
1 |
liver transplantation - adverse effects - immunology - mortality |
1 |
liver transplantation - immunology - mortality |
1 |
liver transplantation - trends |
1 |
living donors - statistics & numerical data |
1 |
living donors - statistics and numerical data |
1 |
maintenance therapy |
1 |
models of care |
1 |
nano-aerosols |
1 |
nephrotoxicity |
1 |
non-operative treatment |
1 |
organ shortage |
1 |
osmolar concentration |
1 |
package charge (住院打包收費) |
1 |
pancreatitis - diagnosis - etiology |
1 |
pandemic |
1 |
patient satisfaction (患者滿意度) |
1 |
postoperative complications - immunology - virology |
1 |
rectal cancer |
1 |
reoperation - statistics & numerical data |
1 |
research design |
1 |
risk |
1 |
sarcoma - diagnosis - pathology |
1 |
sars-cov-2 |
1 |
soft tissue neoplasms - diagnosis - pathology |
1 |
splenic artery - surgery |
1 |
surgical disease (手術病例) |
1 |
thigh - blood supply |
1 |
thrombosis - etiology |
1 |
tissue and organ procurement |
1 |
transanal endoscopic operation |
1 |
transanal total mesorectal excision |
1 |
treatment failure |
1 |